Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
+$1.21 today
- Market cap
- $9.64B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
Volume 1.37M
Average 1.17M
SYRE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Spyre Therapeutics, Inc.NASDAQ: SYRE
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $96.12M (cash outflow) rose 759.5% year over year, ahead of the +77.1% change in trailing-twelve-month net income. Sequentially, it rose 165.5% from the prior quarter. Over 3 fiscal years it compounded at +22.8% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$200.79M (+29.4%) for the fiscal year ending Dec 2026, a step up from the -25.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$96.12M+165.5% QoQ
- Last fiscal yearDec 2025
- -$155.2M-25.4% YoY
- LTMSep 2026
- -$263.86M+77.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +759.5% | +43.2% | -716.4 pp |
| 1 year | -25.4% | +29.4% | +54.8 pp |
| 3-year CAGR | +22.8% | +22.1% | -0.7 pp |
| 5-year CAGR | +16.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (155.2M) USD
- Year-over-year change
- +25.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (155.2M) | +25.4% |
| FY2024 | 2024-12-31 | (208.02M) | +38.6% |
| FY2023 | 2023-12-31 | (338.79M) | -304.2% |
| FY2022 | 2022-12-31 | (83.82M) | -27.4% |
| FY2021 | 2021-12-31 | (65.8M) | — |
Net Income vs competitors
How SYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +77.1% is the 3rd highest of 8, against a peer median of +8.0%.
- Net income amounts to 291.6% of revenue for SYRE, versus a peer median of 832.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €322.84M EUR | +83.2% | +74.5% | — | |
| LTM Sep 2026 | $263.86M USD | +77.1% | +22.8% | 291.6% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $156.76M USD | +98.0% | +81.8% | 4719.0% |
| LTM Mar 2026 | $104.29M USD | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $69.66M USD | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | $58.06M USD | +8.0% | -2.9% | 13.6% | |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $26.79M USD | -81.0% | — | 11.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding SYRE) | — | +8.0% | +5.6% | 832.6% | |
Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.8M) | (83.82M) | (338.79M) | (208.02M) | (155.2M) |
| Depreciation & Amortization | 1.58M | 1.96M | 744K | 0 | 10M |
| Deferred Income Tax | 0 | (327K) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.04M | 7.11M | 25.68M | 44.83M | 37.61M |
| Change in Working Capital | 1.83M | (5.5M) | (5.21M) | (4.53M) | (5.93M) |
| Accounts Receivables | (815K) | 440K | 375K | 0 | 0 |
| Inventory | 0 | (440K) | 0 | 0 | 0 |
| Accounts Payables | 1.07M | (2.64M) | 218K | (230K) | 7.65M |
| Other Working Capital | 1.58M | (2.86M) | (5.8M) | (4.3M) | (13.58M) |
| Other Non-Cash Items | 638K | 426K | 217.67M | 10.31M | (55.73M) |
| Operating Cash Flow | (53.72M) | (80.14M) | (99.91M) | (157.41M) | (169.25M) |
| Capital Expenditures | (573K) | (38K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 3.04M | 0 | 0 |
| Purchases of Investments | (133.08M) | (39.5M) | (166.8M) | (599.25M) | (522.21M) |
| Sales of Investments | 111.03M | 96.55M | 39.9M | 245.97M | 371.74M |
| Other Investing Activities | 0 | 0 | 15.48M | 0 | 7M |
| Investing Cash Flow | (22.62M) | 57.01M | (108.39M) | (353.29M) | (143.48M) |
| Debt Repayment | (510K) | (418K) | (16K) | 0 | 0 |
| Common Stock Issued | 0 | 42.87M | 169.11M | 236.38M | 314.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.9M | 222K | (5.38M) | 5.67M | (5.41M) |
| Financing Cash Flow | 1.39M | 42.68M | 361.08M | 410.91M | 309.03M |
| Effect of Forex Changes | (15K) | (106K) | 25K | (3K) | 0 |
| Net Change in Cash | (74.96M) | 19.44M | 152.8M | (99.79M) | (3.7M) |
| Free Cash Flow | (54.29M) | (80.18M) | (99.91M) | (157.41M) | (169.25M) |
Spyre Therapeutics, Inc.
NASDAQ:SYRE
Intrinsic Alpha fair value
Locked
Current Price
$101.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.